Management of Potential Long-Term Toxicities in Breast Cancer Patients

Abstract

Breast cancer is the most common non-cutaneous malignancy among women, and there are over 3 million breast cancer survivors living in the United States today. Excellent cure rates with modern therapies are associated with substantial toxicities for many women; it is important that health care providers attend to the resulting symptoms and issues to optimize quality of life in this population. In this article, we review management options for potential long term toxicities in breast cancer survivors, with a particular focus on bone health, fertility preservation, premature menopause, cardiac dysfunction, and cognitive impairment.

Characterisation of estrogen receptor alpha (ERα) expression in breast cancer cells and effect of drug treatment using targeted nanoparticles and SERS

“…41 However, like all hormonal therapy drugs, fulvestrant is known to have side effects, such as decreased white blood cells, abnormal liver function and increased risk of infections. 40,42 The ability to understand the efficacy of fulvestrant is important for improving the way that the drug is used clinically. Therefore, we used our SERS approach to determine the activity of fulvestrant in MCF-7 cells.…”

Updates in the Evaluation and Management of Breast Cancer

“…Furthermore, attention to potential late and/or long-term toxicities such as osteopenia/osteoporosis, infertility, premature menopause, cardiac dysfunction, and cognitive impairment is essential. 116 Patients can greatly benefit from targeted exercise programs, lifestyle modifications, integrative approaches, and psychological and social support. 117 Given that patients with metastatic breast cancer often have unique issues and concerns, 118 there are dedicated support groups for these patients.…”

Effect of metformin as an adjuvant therapy to letrozole on estradiol and other biomarkers involved in the pathogenesis of breast cancer in overweight and obese postmenopausal women: a pilot study

“…About two thirds of estrogen and/or progesterone receptors are expressed in about two thirds of breast tumors. Consequently, blocking estrogen signaling in cancer cells is essential during the treatment of breast cancer [2].…”